Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Diabesity: the new epidemic
- Global prevalence of obesity
- Global prevalence of type 2 diabetes
- Diabetes and obesity
- Types of bariatric surgery
- Feeding and gut peptides
- L-cell secretions
- Peptide YY (PYY)
- Peptide metabolism
- Peptide YY (PYY) metabolism
- Peptide YY (PYY) entities
- PYY molecules and PYY receptors
- NPY receptor signalling
- Peptide YY (PYY) – what do we know?
- Peptide YY (PYY) – what we are learning
- PYY and appetite/glucose regulation
- PYY in diabetes
- PYY(1-36) and insulin secretion
- PYY(1-36) and islet morphology
- PYY in diabetes
- PYY in pancreatic islets
- PYY and RYGB surgery
- Intra-islet PYY in diabetes after RYGB surgery
- What's next?
- Unimolecular gut peptide pharmacology
- Unimolecular GLP-1/PYY pharmacology
- PYY(1-36) therapies for diabetes
- Concluding remarks
Topics Covered
- Worldwide epidemic proportions of obesity and diabetes (diabesity)
- Signaling pathways and function of gut hormones in diabetes and obesity
- Structure and function of Peptide YY (PYY)
- PYY levels after bariatric surgery (a potential cure for diabesity)
- Long-acting PYY analogues for the treatment of diabesity
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Irwin, N. (2018, August 29). Peptide YY (PYY) in obesity and diabetes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/RFTU5427.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Nigel Irwin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
I am Dr. Nigel Irwin from
the University of Ulster School of Pharmacy and Pharmaceutical Sciences.
This presentation is on peptide YY or PYY for short,
and its role in obesity and diabetes.
Essentially the talk will cover,
the idea that PYY can be used as a therapeutic for
both obesity and quite recently it can also be used for diabetes.
0:23
This is just some background into the area that I'm going to
discuss today: obesity and diabetes.
They're often grouped under
the same heading diabesity, because they're both very much linked diseases.
Indeed diabesity is considered the new epidemic of the 21st century,
and numbers are increasing at an alarming rate.
It is for that reason that we need to develop drugs to
both manage glucose control in diabetes,
but also with body weight issues in obesity.
0:51
So this is just some background into the number
of people presenting with obesity worldwide.
This data is from 2014,
and unfortunately numbers will have increased in the past two or three years.
However there is some alarming things to note on this figure.
You can see all the areas shaded in red, have an obesity rate greater than 25 percent.
So one in every four-person presents with obesity; with
a BMI greater than 30 kilograms per meter squared,
and these numbers, as I said are increasing at a very steady rate.
1:25
The story unfortunately, is exactly the same with type two diabetes.
We can see here some data from 1980 right through to 2014.
So again these numbers will have also increased in the past couple of years, since 2014,
but as you can see over that 30 year period,
there has been a remarkable increase in the number of
people presenting with type two diabetes. In particular
some regions of the world, where the increase has been
more than double, so places like the East Mediterranean region:
you can see it increased from 5.9 percent to 13.7 percent over that 35-year period
and this is steadily increasing.
Indeed if we look at the total number of people
presenting with type two diabetes in 2014,
it's an amazing 422 million people worldwide,
which accounts for about 8.5 percent of the total population.
So both obesity and diabetes are steadily increasing, year on year.